Post on 26-Feb-2018
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 1/113
Case
Analysis
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 2/113
Analysis
CEO:
Jefrey B. Kindler (2006 -2010)
Location: New York, USA (Corpor!e "ed#$r!er%)
Web Site Address: &!!p'www.p*er.+o
Stock Exchange Listings: New York S!o+k +&n/e ()
ondon (3)
$rone!
Swi%%
%! +!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 3/113
4&e "i%!ory o5*er
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 4/113
1849 o$ndedC&rle%*er
Copny
186
ir%!
doe%!i+prod$+!ion o5!r!ri+ +id +re o5
!r!r
188!
Be/$n
prod$+!iono5 +i!ri+
+id
1891
7e!& o5C&rle%r&r!
4&e "i%!ory o5 *er
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 5/113
19!!
8fered%&re%o5
+oon %!o+k!o !&e
p$9li+
1919
S$++e%%5$llypioneered%%
prod$+!ion o5+i!ri+ +id5ro %$/r
198
Alenderlein/di%+o:ered
!&en!i9io!i+proper!ie%
o5
peni+illinold
19"6
7e:eloped5eren!!io
n 5reee!&od 5orprod$+in/%+or9i+
+id
4&e "i%!ory o5 *er
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 6/113
4&e "i%!ory o5 *er
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 7/113
4&e "i%!ory o5 *er
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 8/113
4&e "i%!ory o5 *er
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 9/113
Key rod$+!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 10/113
&r+e$!i+l%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 11/113
Crdio:%+$lr nd
;e!9oli+ 7i%e%e%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 12/113
Cen!rl Ner:o$% Sy%!e
7i%order%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 13/113
Ar!&ri!i% ndin
Urolo/y
8p&!&lolo/y
ndo+rine 7i%order
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 14/113
<n5e+!io$% nd
=e%pir!ory 7i%e%e%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 15/113
8n+olo/y
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 16/113
Anil "el!&
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 17/113
Anil "el!&
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 18/113
;i%%ion nd >i%ionS!!een!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 19/113
?e dedi+!e o$r%el:e% !o
&$ni!y@% #$e%! 5or lon/er,&el!&ier, &ppier li:e% !&ro$/&inno:!ion in p&r+e$!i+l,+on%$er, nd nil &el!&
prod$+!%.
>i%ion
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 20/113
?e will 9e+oe !&e world@% o%!
:l$ed +opny !o p!ien!%,+$%!oer%, +olle/$e%, in:e%!or%,9$%ine%% pr!ner%, nd !&e+o$ni!ie% w&ere we work nd
li:e.
;i%%ion
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 21/113
<n!ernlA%%e%%en!
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 22/113
inn+il Anly%i%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 23/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 24/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 25/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 26/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 27/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 28/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 29/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 30/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 31/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 32/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 33/113
inn+il C&r!%
2006 200 20010D,000
110,000
111,000
112,000
11E,000
11F,000
11G,000
116,000
11F,E
11G,26
111,1F
Assets #in $illions%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 34/113
inn+il C&r!%
2006 200 2000
10,000
20,000
E0,000
F0,000
G0,000
60,000
FE,FD
G0,2GGE,GD2
Liabilities #in $illions%
inn+il C&r!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 35/113
inn+il C&r!%
2006 200A 200BCF1,000
CF2,000
CFE,000
CFF,000
CFG,000
CF6,000
CFA,000
CFB,000
CF6,DFDCF6,BFD
CFE,0A6
C&rrent Assets #in $illions%
inn+il C&r!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 36/113
inn+il C&r!%
2006 200 2000
G,000
10,000
1G,000
20,000
2G,000
E0,000
21,ED 21,EG
2,00D
C&rrent Liabilities #in $illions%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 37/113
inn+il =!io%
1 2 E0.0
0.G
1.0
1.G
2.0
2.G
2.2 2.1
1.6
C&rrent 'atio
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 38/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 39/113
inn+il C&r!%
2006 200 2000
10,000
20,000
E0,000
F0,000
G0,000
60,000
0,000
0,000
1,EG6G,010
G,GG6
Stockholders* e+&ity #in $illions%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 40/113
inn+il =!io%
2006 200 200 2006 0 00.0
0.1
0.1
0.2
0.2
0.E
0.E
0.1
0.1
0.E
Long (er$ )ebt to E+&ity 'atio
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 41/113
inn+il C&r!%
2006 200A 200BC10D,000
C110,000
C111,000
C112,000
C11E,000
C11F,000
C11G,000
C116,000
C11F,BEA
C11G,26B
C111,1FB
Assets #in $illions%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 42/113
inn+il C&r!%
2006 200 2000
G,000
10,000
1G,000
20,000
2G,000
1D,EE
,1FF ,10F
,et -nco$e #in $illions%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 43/113
inn+il =!io%
2006 200 200 2006 0 00.0
0.0
0.0
0.1
0.1
0.1
0.1
0.1
0.2
0.20.2
0.1 0.1
'O-
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 44/113
inn+il C&r!%
2006 200 2000
10,000
20,000
E0,000
F0,000
G0,000
60,000
0,000
0,000
1,EG6G,010
G,GG6
Stockholders* e+&ity #in $illions%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 45/113
inn+il C&r!%
2006 200 2000
G,000
10,000
1G,000
20,000
2G,000
1D,EE
,1FF ,10F
,et -nco$e #in $illions%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 46/113
inn+il =!io%
2006 200 200 2006 0 00.0
0.1
0.1
0.2
0.2
0.E
0.E0.E
0.10.1
'OE
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 47/113
;n/een! Anly%i%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 48/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 49/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 50/113
;rke!in/ Anly%i%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 51/113
C$rren! ;rke!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 52/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 53/113
?e will 9e re+o/ni*ed 5or ee!in/ !&e
di:er%e edi+l need% o5 p!ien!% in
er/in/ ;rke!% ro$nd !&e world inn inno:!i:e, %o+illy re%pon%i9le, nd+oer+illy :i9le nner.
>i%ion
(er/in/ ;rke!%)
i i
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 54/113
?e will H
7e:elop 9old nd inno:!i:e pr!ner%&ip%
=e+& p!ien!% we &:e ne:er re+&ed 9e5ore ro:ide edi+ine% nd %er:i+e% in n
ford9le nner
Be re+o/ni*ed in &:in/ !&e 9e%! !len! in
&el!&+re Be+oe ledin/ 9iop&r+e$!i+l
+opny in er/in/ ;rke!%
;i%%ion
(er/in/ ;rke!%)
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 55/113
=e%er+& nd7e:elopen!
=7 ili!i @
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 56/113
=7 +ili!ie%@
o+!ion
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 57/113
-+oer+e
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 58/113
*er.+o
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 59/113
S!ren/!&% nd?ekne%%e%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 60/113
8ne o5 !&e lr/e%! p&r+e$!i+l +opny in !&e
world nd %pred o:er ore !&n G0 +o$n!rie%
+ellen! re%er+& nd de:elopen! (=7)+re!in/ inno:!i:e nd 9rek!&ro$/& prod$+!%
;er/er% nd +#$i%i!ion% wi!& 9i/ p&r+e$!i+l+opnie% in+re%in/ 9rnd rep$!!ion
"% o:er 100,000 eployee% % pr! o5 !&e
or/ni*!ion
S!ron/ 9rnd ne nd re+ll /lo9lly
S!ren/!&%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 61/113
N$9er one p&r+e$!i+l 5ro %le% poin! o5 :iew
nd i!% rke!in/ in5r%!r$+!$re i% well e%!9li%&ed!&ro$/&o$! !&e world
4&erpe$!i+ +o:er/e i% :ery lr/e nd !&einno:!i:e re%er+&er% re 9rodenin/ i! 5$r!&er
?ell e%!9li%&ed rep$!!ion 5or yer% on n$9er o5prod$+!%
?ide rn/e o5 re 9ein/ worked, !&! in+l$de%&$n &el!&, nil &el!&, +$%!oer &el!&, nd+orpor!e /ro$p%
<n:ol:ed in li+en%in/ /reeen!% wi!& diferen!+opnie% 5or +oll9or!i:e re%er+& work
S!ren/!&%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 62/113
4o$/& +ope!i!ion 5ro o!&er or p&r+e$!i+l
9rnd% en% lii!ed %+ope 5or rke! %&re /row!&
Ne/!i:e 9rnd i/e d$e !o in:ol:een! in lr/e%!&el!&+re 5r$d o5 rke!in/ i!% dr$/ ille/lly
>ery lii!ed pene!r!ion o5 9iolo/i+% rke!
;rke!in/ wi!& o!&er +opnie% nd er/in/ wi!&
o!&er p&r+e$!i+l% +n &l!er i!% /lo9l
pop$lri!y 8:errelin+e on !&e !$re rke! (U.S.) nd %ll
n$9er o5 di%!ri9$!or%
?ekne%%e%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 63/113
<rr!ionl dr$/ poli+ie% %$+& % 9rin/in/ o:er 0
per+en! o5 !&e dr$/% $nder pri+e +on!rol
<nde#$!e in5r%!r$+!$re 5or 5eren!!ion-9%eddr$/ reedie% nd e$en! !re!en! pln!%
+k o5 or inde#$!e %$9%idie% nd %+l in+en!i:e%
5or !&e ind$%!ry
<nde#$!e #$li!y !e%!in/ 5+ili!ie% 5or !&e re/$l!ory
$!&ori!ie%, w&i+& &:e ore dini%!r!i:e nd le%%!e+&ni+l +p9ili!ie% % re%$l!
ii!ed ei%%ion ri/&!%
?ekne%%e%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 64/113
<n!ernl +!or
:l$!ion (<);!ri
-nternal .actor E/al&ation 0atrix #-.E%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 65/113
-nternal .actor E/al&ation 0atrix #-.E%
Strengths Weight Rating
Weighted
Score
1. 8ne o5 !&e lr/e%! p&r+e$!i+l +opny in !&e world nd %pred o:er ore!&n G0 +o$n!rie%
0.0E F 0.12
2. +ellen! re%er+& nd de:elopen! (=7) +re!in/ inno:!i:e nd
9rek!&ro$/& prod$+!%0.0G E 0.1G
E. ;er/er% nd +#$i%i!ion% wi!& 9i/ p&r+e$!i+l +opnie% in+re%in/ 9rndrep$!!ion
0.0 F 0.2
F. "% o:er 100,000 eployee% % pr! o5 !&e or/ni*!ion 0.0F E 0.12
G. S!ron/ 9rnd ne nd re+ll /lo9lly 0.0 E 0.21
6. N$9er one p&r+e$!i+l 5ro %le% poin! o5 :iew nd i!% rke!in/in5r%!r$+!$re i% well e%!9li%&ed !&ro$/&o$! !&e world
0.0G F 0.20
. 4&erpe$!i+ +o:er/e i% :ery lr/e nd !&e inno:!i:e re%er+&er% re9rodenin/ i! 5$r!&er
0.0E E 0.0D
. ?ell e%!9li%&ed rep$!!ion 5or yer% on n$9er o5 prod$+!% 0.0G E 0.1GD. ?ide rn/e o5 re 9ein/ worked, !&! in+l$de% &$n &el!&, nil &el!&,
+$%!oer &el!&, nd +orpor!e /ro$p%0.0F F 0.16
10. <n:ol:ed in li+en%in/ /reeen!% wi!& diferen! +opnie% 5or +oll9or!i:ere%er+& work 0.0 E 0.21
Weaknesses Weight 'atingWeighted Score
1. 4o$/& +ope!i!ion 5ro o!&er or p&r+e$!i+l 9rnd% en% lii!ed %+ope5or rke! %&re /row!& 0.0 2 0.16
2. Ne/!i:e 9rnd i/e d$e !o in:ol:een! in lr/e%! &el!&+re 5r$d o5rke!in/ i!% dr$/ ille/lly
0.0G 2 0.10
E. >ery lii!ed pene!r!ion o5 9iolo/i+% rke! 0.0D 2 0.1
F. ;rke!in/ wi!& o!&er +opnie% nd er/in/ wi!& o!&er p&r+e$!i+l% +n&l!er i!% /lo9l pop$lri!y
0.0G E 0.1G
G. 8:errelin+e on !&e !$re rke! (U.S.) nd %ll n$9er o5 di%!ri9$!or% 0.02 2 0.0F
6. <rr!ionl dr$/ poli+ie% %$+& % 9rin/in/ o:er 0 per+en! o5 !&e dr$/% $nder pri+e
+on!rol
0.0E F 0.12
. <nde#$!e in5r%!r$+!$re 5or 5eren!!ion-9%ed dr$/ reedie% nd e$en!0.0F E 0.12
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 66/113
!ernlA%%e%%en!
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 67/113
Cope!i!i:e or+e%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 68/113
Cope!i!or%
0erck 2 Co
- >++ine%
- re%+rip!ion 7r$/% - Con%$er rod$+!%
- Anil "el!&
S!r!e/ie%'• ;er/er% nd A+#$i%i!ion%• rod$+! 7e:elopen!• ;rke! 7e:elopen!• r!ner%&ip%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 69/113
Cope!i!or%
3ayer A
- Byer "el!&Cre
- Byer CropS+ien+e
- Byer ;!erilS+ien+e
S!r!e/ie%'• Corpor!e So+il =e%pon%i9ili!y• Unrel!ed 7i:er%i+!ion• ;er/er% nd A+#$i%i!ion%• rod$+! 7e:elopen!
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 70/113
Cope!i!or%
,o/artis A
- &r+e$!i+l
- Al+on L ye +re- Sndo* L Meneri+%
- 8:er-!&e-+o$n!er
S!r!e/ie%'• rod$+! 7e:elopen!• =el!ed 7i:er%i+!ion• ;er/er% nd A+#$i%i!ion%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 71/113
Cope!i!i:e role;!ri (C;)
C;
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 72/113
Competitive Profile Matrix (CPM)
PFIZER NOVARTIS MERCK Co. BAYER
Critical Success FactorsWeigh
tRating Score Rating Score Rating Score Rating Score
Advertising 0.05 4 0.20 3 0.15 3 0.15 3 0.15
Market Penetration 0.10 3 0.30 3 0.30 4 0.40 3 0.30
Customer Service 0.09 4 0.36 2 0.18 4 0.36 3 0.27
Store Locations 0.04 4 0.16 2 0.08 3 0.12 2 0.08
R&D 0.14 3 0.42 4 0.56 4 0.56 3 0.42
Employee Dedication 0.09 3 0.27 2 0.18 4 0.36 3 0.27
Financial Profit 0.10 4 0.40 4 0.40 2 0.20 4 0.40
Customer Loyalty 0.06 3 0.18 2 0.12 3 0.18 3 0.18
Market Share 0.10 4 0.40 3 0.30 2 0.20 2 0.20Product Quality 0.09 3 0.27 3 0.27 3 0.27 3 0.27
Top Management 0.05 3 0.15 3 0.15 2 0.10 2 0.10
Price Competitiveness 0.09 3 0.27 4 0.36 3 0.27 3 0.27
Totals 1.00 3.38 3.05 3.17 2.91
C;
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 73/113
+onoi+ <%%$e%
U S +onoy
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 74/113
*er %$fered 5ro %lowdown in %le% 5!er
ny o5 i!% dr$/% wen! of p!en! nd /eneri+-dr$/ +opnie% po+&ed %le%. 4&e dr$/ker w% 5or+ed !o +$! =7 %pendin/ ndpre !&e %i*e o5 i!% %le% 5or+e in 200.
U.S. +onoy
=e+e%%ion
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 75/113
ropo%ed A+#$i%i!iono5 ?ye!&
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 76/113
o!en!il Bene!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 77/113
8ppor!$ni!ie% nd 4&re!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 78/113
S!r!e/i+ /reeen!% wi!& o!&er
p&r+e$!i+l +opnie% ndor/ni*!ion% !o 9oo%! i!% re%er+&.
<n+re%in/ wrene%% o5 people 9o$! !&eir&el!&+re need%
Mlo9l pene!r!ion !&ro$/& er/er% nd
+#$i%i!ion% <n+re%in/ dend 5or #$li!y &el!&+re
%ol$!ion%
=e%!r$+!$rin/ %!r!e/y de%i/ned !o +$!
+o%!% nd lener +opny
8ppor!$ni!ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 79/113
$ndin/ :il9le !o 5+ili!!e
prod$+!+opny
A+#$i%i!ion% (?ye!&) nd in-li+en%in/+o-de:elopen! oppor!$ni!ie%
pn%ion in!o 9iolo/i+% rke!
-Coer+e
"i/& pro!%, re:en$e% nd 5$nd% re:il9le !o $pli5! !&e +opny% pro/re%%
8ppor!$ni!ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 80/113
=i%k o5 $n%$++e%%5$l new prod$+!%
=e/$l!ory en:ironen! i% 9e+oin/
ore ore %!rin/en! +onoi+ %lowdown in $ropen
rke!%
<n+re%ed rke! +ope!i!ion%
o%in/ o5 p!en! indi:id$li!y 9y5o+$%in/ on one prod$+!
4&re!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 81/113
o%% o5 p!en! pro!e+!ion o5 or prod$+!%
=i%k o5 i%i !erin!in/ lon/-%!ndin/
pr!ner%&ip 8$!%!ndin/ +ope!i!ion o5 re/ionl rke!%
lon/ wi!& eer/in/ rke!% o5 <ndi ndC&in
Ne/!i:ely p$9li+i*ed 9y 9ein/ %$ed 9y !&eir+$%!oer%
"el!&+re re5or in !&e US fe+!% re:en$e/row!&
4&re!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 82/113
!ernl +!or
:l$!ion ();!ri
External .actor E/al&ation 0atrix #E.E%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 83/113
O55ort&nities Weight 'atingWeighted Score
1. S!r!e/i+ /reeen!% wi!& o!&er p&r+e$!i+l +opnie% nd or/ni*!ion% !o9oo%! i!% re%er+&.
0.0D E 0.2
2. <n+re%in/ wrene%% 9o$! &el!&+re need% 0.06 E 0.1
E. Mlo9l pene!r!ion !&ro$/& er/er% nd +#$i%i!ion% 0.0 F 0.2F. <n+re%in/ dend 5or #$li!y &el!&+re %ol$!ion% 0.0 E 0.21
G. =e%!r$+!$rin/ %!r!e/y de%i/ned !o +$! +o%!% nd lener +opny 0.0E E 0.0D
6. $ndin/ :il9le !o 5+ili!!e prod$+!+opny 0.02 E 0.06
. A+#$i%i!ion% (?ye!&) nd in-li+en%in/+o-de:elopen! oppor!$ni!ie% 0.0 F 0.2
. pn%ion in!o 9iolo/i+% rke! 0.0G E 0.1G
D. -Coer+e 0.0E 2 0.06
10. "i/& pro!%, re:en$e% nd 5$nd% re :il9le !o $pli5! !&e +opny% pro/re%% 0.0F F 0.16
(hreats Weight 'atingWeighted Score
1. =i%k o5 $n%$++e%%5$l new prod$+!% 0.0F 2 0.0
2. =e/$l!ory en:ironen! i% 9e+oin/ ore ore %!rin/en! 0.0G E 0.1G
E. +onoi+ %lowdown in $ropen rke!% 0.0E 2 0.06
F. <n+re%ed rke! +ope!i!ion% 0.06 E 0.1
G. o%in/ o5 p!en! indi:id$li!y 9y 5o+$%in/ on one prod$+! 0.0 E 0.2F
6. o%% o5 p!en! pro!e+!ion o5 or prod$+!% 0.0 F 0.2. =i%k o5 i%i !erin!in/ lon/-%!ndin/ pr!ner%&ip 0.0F E 0.12
. 8$!%!ndin/ +ope!i!ion o5 re/ionl rke!% lon/ wi!& eer/in/ rke!% o5<ndi nd C&in
0.0E 2 0.06
D. Ne/!i:ely p$9li+i*ed 9y 9ein/ %$ed 9y !&eir +$%!oer% 0.0F F 0.16
10. "el!&+re re5or in !&e US fe+!% re:en$e /row!& 0.0E E 0.0D
(O(ALS 1!! 88
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 84/113
S!r!e/yor$l!ion
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 85/113
S?84 ;!ri
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 86/113
1. 8ne o5 !&e lr/e%! p&r+e$!i+l +opny in !&e world nd %predo:er ore !&n G0 +o$n!rie%
2. +ellen! re%er+& nd de:elopen! (=7) +re!in/ inno:!i:e nd9rek!&ro$/& prod$+!%
E. ;er/er% nd +#$i%i!ion% wi!& 9i/ p&r+e$!i+l +opnie%in+re%in/ 9rnd rep$!!ion
F. "% o:er 100,000 eployee% % pr! o5 !&e or/ni*!ion
G. S!ron/ 9rnd ne nd re+ll /lo9lly
6. N$9er one p&r+e$!i+l 5ro %le% poin! o5 :iew nd i!%rke!in/ in5r%!r$+!$re i% well e%!9li%&ed !&ro$/&o$! !&e world
. 4&erpe$!i+ +o:er/e i% :ery lr/e nd !&e inno:!i:e re%er+&er% re9rodenin/ i! 5$r!&er
. ?ell e%!9li%&ed rep$!!ion 5or yer% on n$9er o5 prod$+!%
D. ?ide rn/e o5 re 9ein/ worked, !&! in+l$de% &$n &el!&, nil&el!&, +$%!oer &el!&, nd +orpor!e /ro$p%
10. <n:ol:ed in li+en%in/ /reeen!% wi!& diferen! +opnie% 5or
+oll9or!i:e re%er+& work
S!ren/!&%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 87/113
1. 4o$/& +ope!i!ion 5ro o!&er or p&r+e$!i+l 9rnd% en%
lii!ed %+ope 5or rke! %&re /row!&
2. Ne/!i:e 9rnd i/e d$e !o in:ol:een! in lr/e%! &el!&+re 5r$do5 rke!in/ i!% dr$/ ille/lly
E. >ery lii!ed pene!r!ion o5 9iolo/i+% rke!
F. ;rke!in/ wi!& o!&er +opnie% nd er/in/ wi!& o!&erp&r+e$!i+l% +n &l!er i!% /lo9l pop$lri!y
G. 8:errelin+e on !&e !$re rke! (U.S.) nd %ll n$9er o5di%!ri9$!or%
6. <rr!ionl dr$/ poli+ie% %$+& % 9rin/in/ o:er 0 per+en! o5 !&e dr$/%
$nder pri+e +on!rol. <nde#$!e in5r%!r$+!$re 5or 5eren!!ion-9%ed dr$/ reedie% nd
e$en! !re!en! pln!%
. +k o5 or inde#$!e %$9%idie% nd %+l in+en!i:e% 5or !&e ind$%!ry
D. <nde#$!e #$li!y !e%!in/ 5+ili!ie% 5or !&e re/$l!ory $!&ori!ie%,w&i+& &:e ore dini%!r!i:e nd le%% !e+&ni+l +p9ili!ie% %
re%$l!
?ekne%%e%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 88/113
1. S!r!e/i+ /reeen!% wi!& o!&er p&r+e$!i+l +opnie% nd
or/ni*!ion% !o 9oo%! i!% re%er+&.
2. <n+re%in/ wrene%% 9o$! &el!&+re need%
E. Mlo9l pene!r!ion !&ro$/& er/er% nd +#$i%i!ion%F. <n+re%in/ dend 5or #$li!y &el!&+re %ol$!ion%
G. =e%!r$+!$rin/ %!r!e/y de%i/ned !o +$! +o%!% nd lener +opny
6. $ndin/ :il9le !o 5+ili!!e prod$+!+opny
. A+#$i%i!ion% nd in-li+en%in/+o-de:elopen! oppor!$ni!ie%
. pn%ion in!o 9iolo/i+% rke!
D. -Coer+e
10."i/& pro!%, re:en$e% nd 5$nd% re :il9le !o $pli5! !&e+opny% pro/re%%
8ppor!$ni!ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 89/113
1. =i%k o5 $n%$++e%%5$l new prod$+!%
2. =e/$l!ory en:ironen! i% 9e+oin/ ore ore %!rin/en!
E. +onoi+ %lowdown in $ropen rke!%
F. <n+re%ed rke! +ope!i!ion%G. o%in/ o5 p!en! indi:id$li!y 9y 5o+$%in/ on one prod$+!
6. o%% o5 p!en! pro!e+!ion o5 or prod$+!%
. =i%k o5 i%i !erin!in/ lon/-%!ndin/ pr!ner%&ip
. 8$!%!ndin/ +ope!i!ion o5 re/ionl rke!% lon/ wi!&
eer/in/ rke!% o5 <ndi nd C&inD. Ne/!i:ely p$9li+i*ed 9y 9ein/ %$ed 9y !&eir +$%!oer%
10."el!&+re re5or in !&e US fe+!% re:en$e /row!&
4&re!%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 90/113
<! +n $%e i!% rep$!!ion % one o5 !&e lr/e%!
p&r+e$!i+l +opny in !&e world !o /in
%!r!e/i+ /reeen!% wi!& o!&er +opnie%nd or/ni*!ion% !o 9oo%! i!% re%er+& (S1,81)
<! +n $%e i!% 5$lly in!e/r!ed n$5+!$rin/5+ili!ie% !o epnd in!o !&e 9iolo/i+% rke!
(S10, 8)
<! +n $%e i!% rke!in/ in5r%!r$+!$re !o &:e rke!in/ /reeen!% wi!& ledin/+opnie% (S6 810)
S8 S!r!e/ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 91/113
<! +n $%e i!% e+ellen! re%er+& nd
de:elopen! (=7) pro/r !o red$+e !&e
!&re!% or $n%$++e%%5$l new prod$+!% (S2 41) <! +n $%e i!% er/er% nd +#$i%i!ion%%!r!e/ie% !o red$+e !&e in+re%in/ rke!+ope!i!ion (SE 4F)
<!% %!ron/ 9rnd ne nd re+ll /lo9lly +nred$+e !&e !&re!% /i:en 9y in+re%in/ en!rie%o5 pri:!e indi:id$l% (SG 4D)
S4 S!r!e/ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 92/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 93/113
Allo+!e 5$r!&er re%er+& efor!% 9e5ore new
ind$+!ion% in !&e rke! (?6 41)
$nd +pi!l ependi!$re% on in5r%!r$+!$re%5or 5eren!!ion-9%ed dr$/ reedie% nde$en! !re!en! pln!% (? 41)
ro:ide dded rke!in/ efor!% !o re/in n++ep!9le p$9li+ i/e 5or pre:io$%ly %$edprod$+!% (?1 4)
?4 S!r!e/ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 94/113
SAC ;!ri
SAC ;!ri
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 95/113
FINANCIAL POSITION STABILITY POSITION
Return on Investment (ROI) 3 Rate of Inflation -
Levera!e " Te#$nolo!i#al C$an!es -3
Li%ui&it' Pri#e lasti#it' of *eman& -
+or,in! Caital Cometitive Pressure -
Cas$ Flo. Barriers to ntr' into /ar,et -3
Financial Position (FP) Average 4.6 Stability Position (SP) Average -3.6
CO/PTITI0 POSITION IN*1STRY POSITION
/ar,et S$are -2 ro.t$ Potential
Pro&u#t 4ualit' -3 Finan#ial Sta5ilit' 3
Customer Lo'alt' -2 ase of ntr' into /ar,et
Te#$nolo!i#al ,no.-$o. - Resour#e 1tili6ation
Control over Suliers an& -2 Profit Potential
SAC ;!ri
Con%er:!i:e A//re%%i:e
7
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 96/113
7axis 14
6 axis 1!
G
F
E
2
1
C - -6 -G -F -E -2 -1 1 2 E F G 6 < -1
-2
-E
-F
-G
-6
-7e5en%i:e S Cope!i!i:e
7 <n!e/r!ionS!r!e/ie%7 ;rke! ene!r!ion7 ;rke! 7e:elopen!7 7i:er%i+!ion
S!r!e/ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 97/113
BCM ;!ri
BCM ;A4=<O
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 98/113
*ivision 5' eo!ra$i# Area
#S International
Pro$its 8932"92:9::: 2:9:;9:::9:::
%even!es 2:939:::9::: 2<9="89:::9:::
BCM ;A4=<O
Relative Market Share Position
High Medium
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 99/113
Low
High+20
1.0 .50
0.0
S!r P$e%!ion ;rk
Medium
0
C%& Cow 7o/
<n!ern!ionl
US
BCM ;A4=<O
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 100/113
BCM ;A4=<O
7i:i%ion 9y B$%ine%% Se/en!
&r+e$!i+l% Anil &el!& Corpor!e8!&er
ro;ts EG,EED,200,000 2,11,G0,000 ,200,000
'e/en&es FF,1F,000,000 2,2G,000,000 1,2D,000,000
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 101/113
Relative Market Share Position
High Medium Low
High+20 1.0 .50 0.0
S!r P$e%!ion ;rk
Medium 0
C%& Cow 7o/
Corpor!e
Anil "el!&
&r+e$!i+
l%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 102/113
<n!ernl-!ernl;!ri
(he (otal -.E Weighted Scores
S!ron/ A:er/e ?ek
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 103/113
S!ron/ A:er/e ?ek
F.0 !o E.0 2.DD !o 2.0 1.DD !o 1.0F.0 < << <<<
"i/&
E.0 <> > ><
*er
< L E.06 L E.0 ro< and 3&ild
7 <n!e/r!ion S!r!e/ie%7 <n!en%i:e S!r!e/ie%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 104/113
Mrnd S!r!e/y;!ri
=pid ;rke! Mrow!&
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 105/113
P$drn! << P$drn! <
?ekCope!i!i:e
o%i!ion
S!ron/
Cope!i!i:eo%i!ion
P$drn! <<< P$drn! <>
Slow ;rke! Mrow!&
*er
7 <n!e/r!ionS!r!e/ie%
7 <n!en%i:e S!r!e/ie%7 =el!ed
7i:er%i+!ion
P !i! !i
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 106/113
P$n!i!!i:e
S!r!e/i+ lnnin/;!ri
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 107/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 108/113
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 109/113
=e+oend!ion%
= d !i
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 110/113
4&ere5ore we re+oend !&e +opny !o +on!in$e
in +#$irin/ ?ye!& 5or i! &% !&e &i/&e%! %$ o5 !o!lAl!ern!i:e %+ore o5 6.F1.
Sin+e !&e p!en! o5 i%i@% Ari+ep! will epire on 2010!&e +opny need !o in+re%e i!% 5$nd% in re%er+&
nd de:elopen! %o !&! i! +n de:elop newprod$+!% !o +$re di%e%e%.
B$! %in+e *er 5$nd 5or re%er+& nd de:elopen! i%no! !&! &i/&, i! i% 9e!!er !o +#$ire %ll +opny
r%! !o in+re%e ore %le% 9e5ore !&e +opny +nin+re%e i!% re%er+& nd de:elopen! 5$nd%.
=e+oend!ion
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 111/113
S!r!e/y<pleen!!ion
! !i l =i k
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 112/113
=e/$l!ory "$rdle%
<n+re%e% *er@% de9!%
A%%$p!ion o5 i!i/!ion% o5 ?ye!& Co%! +$!!in/ nd y-of%
o!en!il =i%k%
7/25/2019 Pfizer Case Analysis
http://slidepdf.com/reader/full/pfizer-case-analysis 113/113
nd